Targacept, Inc. Earnings Conference Call (Q4 2012)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Feb 13 Calls Today's Calls

Call Details Targacept, Inc. Earnings Conference Call (Q4 2012) Scheduled to start Wed, Feb 13, 2013, 5:00 pm Eastern -- this event is ongoing now-- Listen to the ongoing live event audio stream About Targacept Inc (NasdaqGS:TRGT) Other Calls  Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the central nervous system. The company’s pipeline of clinical-stage product candidates includes TC-5214, which completed Phase II b clinical trial for treating depressive disorders; AZD3480, which completed Phase II clinical trial in adults with attention deficit/hyperactivity disorder (ADHD) for the treatment of ADHD; AZD1446 that completed multiple Phase I trial for Alzheimer’s disease and ADHD; TC-5619, which is in Phase II clinical trial targeting cognitive dysfunction in schizophrenia and one or more other conditions characterized by cognitive impairment; and TC-6987, which is in Phase I trial targeting disorders characterized by inflammation. It has collaboration agreements with AstraZeneca AB for the development and commercialization of TC-5214 as a treatment for major depressive disorders; and a strategic alliance with GlaxoSmithKline to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. The company was founded in 1997 and is based in Winston-Salem, North Carolina. More Info: Quote | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings